| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C19H14N2O6 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
OSS_128167 is a potent, selective inhibitor of sirtuin 6 (SIRT6), with IC50 values of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. It has anti-HBV activity, inhibiting HBV transcription and replication, and it shows anticancer, anti-inflammatory and antiviral effects[1][2]. It is supplied as a white to light yellow solid (C19H14N2O6, MW 366.32) at 98.92% purity.
Physical & Chemical Properties
| CAS Number | 887686-02-4 |
|---|---|
| Molecular Formula | C19H14N2O6 |
| Molecular Weight | 366.32 g/mol |
| Purity | 98.92% |
| Appearance | Solid |
| Color | White to light yellow |
| SMILES | O=C(C1=CC(NC(C2=CC=CO2)=O)=CC=C1)NC3=CC(C(O)=O)=C(O)C=C3 |
| Target | SIRT6, SIRT2, SIRT1, HBV |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics; Anti-infection |
| Solubility | In Vitro: DMSO: 100 mg/mL (272.99 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 1 year; -20°C, 6 months. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
[1][2]
|
SIRT6 89 μM (IC50) |
SIRT2 751 μM (IC50) |
SIRT1 1578 μM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (272.99 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 1 year) or -20°C (up to 6 months); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.68 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (5.68 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 3
| Composition | 0.5% CMC-Na/saline water |
|---|---|
| Result | 10 mg/mL (27.30 mM); suspension; requires sonication |
Data provided by the manufacturer.
In Vitro
Treatment with OSS_128167 (100 μM; 0-24 hours; BxPC3 cells) raises H3K9 acetylation and also GLUT-1 expression in BxPC-3 cells[1]. In cultured BxPC-3 cells, TNF-α secretion induced by phorbol myristate acetate (PMA) is effectively blunted by OSS_128167, and glucose uptake in cells is increased by OSS_128167 as well[1]. OSS_128167 treatment (100 μM; 96 hours; HepG2.2.15 and HepG2-NTCP cells) lowers HBV core DNA and 3.5-Kb RNA levels significantly. OSS_128167 treatment additionally suppresses secretion of the surface antigen of hepatitis B (HBsAg) and the envelope antigen of hepatitis B (HBeAg), and expression of HBsAg in cell lysates[2]. Chemosensitization is induced by OSS_128167 (200 μM) in primary multiple myeloma (MM) cells (NCI-H929) and also in the melphalan-resistant (LR-5) and doxorubicin-resistant (Dox40) MM cell lines[3].
Western Blot Analysis[1]
| Cell Line | BxPC3 cells |
|---|---|
| Concentration | 100 μM |
| Incubation Time | 0 hours, 2 hours, 6 hours, 18 hours, 24 hours |
| Result | Increased H3K9 acetylation. |
RT-PCR[2]
| Cell Line | HepG2.2.15 and HepG2-sodium taurocholate cotransporting polypeptide (NTCP) cells |
|---|---|
| Concentration | 100 μM |
| Incubation Time | 96 hours |
| Result | Significantly decreased HBV core DNA and 3.5-Kb RNA levels. |
In Vivo
In male HBV transgenic mice, OSS_128167 (50 mg/kg; intraperitoneal injection; every 4 days; for 12 days) treatment markedly suppresses HBV DNA and 3.5-Kb RNA levels[2].
| Animal Model | Male HBV transgenic mice (6-8-week-old)[2] |
|---|---|
| Dosage | 50 mg/kg |
| Administration | Intraperitoneal injection; every 4 days; for 12 days |
| Result | The level of HBV DNA and 3.5-Kb RNA were markedly suppressed in HBV transgenic mice. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism. Signal Transduct Target Ther 2025 Dec 8;10(1):398. PMID: 41354870
Melatonin attenuates atherosclerotic plaque vulnerability through SIRT6-dependent regulation of vascular smooth muscle cells senescence. Redox Biol 2025 Dec:88:103939. PMID: 41308252
Fn14 Controls the SIRT2-Mediated Deacetylation of Slug to Inhibit the Metastasis of Epithelial Ovarian Cancer. Adv Sci (Weinh) 2025 Jul;12(27):e2501552. PMID: 40344622
SIRT6 modulates lesion microenvironment in LPC induced demyelination by targeting astrocytic CHI3L1. J Neuroinflammation 2024 Sep 28;21(1):243. PMID: 39342313
Qige Decoction attenuated non-alcoholic fatty liver disease through regulating SIRT6-PPARα-mediated fatty acid oxidation. Phytomedicine 2025 Mar:138:156395. PMID: 39855055
Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake. Phytomedicine 2023 Mar:111:154661. PMID: 36682299
Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6. Phytomedicine 2022 Sep:104:154276. PMID: 35728388
J Pharm Anal. 2026 Apr 13.
Niacin inhibits vascular calcification via modulating of SIRT1/SIRT6 signaling pathway. Cell Death Discov 2025 Dec 6. PMID: 41353172
Downregulation of hippocampal SIRT6 activates AKT/CRMP2 signaling and ameliorates chronic stress-induced depression-like behavior in mice. Acta Pharmacol Sin 2020 Dec;41(12):1557-1567.
